Page 21234..1020..»

Category Archives: Global News Feed

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Posted: February 13, 2025 at 2:44 am

DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq has accepted Portage’s compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Capital Market (the “Capital Market”) as set forth in Nasdaq Listing Rule 5550(b)(1) whereby the minimum shareholders’ equity is at least $2.5 million or meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income from continued operations of at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.

Continued here:
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Posted in Global News Feed | Comments Off on Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit

Posted: February 13, 2025 at 2:44 am

VANCOUVER, British Columbia and SAN FRANCISCO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in two upcoming investor conferences in March 2025:

See the article here:
Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit

Posted in Global News Feed | Comments Off on Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Posted: February 13, 2025 at 2:44 am

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions.

Read the original post:
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Posted in Global News Feed | Comments Off on Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Illuccix® Approved in the United Kingdom

Posted: February 13, 2025 at 2:44 am

MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).

Continued here:
Illuccix® Approved in the United Kingdom

Posted in Global News Feed | Comments Off on Illuccix® Approved in the United Kingdom

Idorsia publishes the resolutions for the upcoming bondholder meeting

Posted: February 13, 2025 at 2:44 am

Ad hoc announcement pursuant to Art. 53 LR

Excerpt from:
Idorsia publishes the resolutions for the upcoming bondholder meeting

Posted in Global News Feed | Comments Off on Idorsia publishes the resolutions for the upcoming bondholder meeting

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

Posted: February 13, 2025 at 2:44 am

PARIS, FRANCE, 13 February 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024.

See the article here:
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

Posted in Global News Feed | Comments Off on Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to…

Posted: February 13, 2025 at 2:44 am

ORION CORPORATION PRESS RELEASE 13 FEBRUARY 2024 at 8.00 EET

Read the rest here:
EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to...

Posted in Global News Feed | Comments Off on EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to…

Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Posted: February 13, 2025 at 2:44 am

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Originally posted here:
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Posted in Global News Feed | Comments Off on Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results

Posted: February 13, 2025 at 2:44 am

Oslo, Norway, 13th of February 2025

Read more from the original source:
Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results

Posted in Global News Feed | Comments Off on Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results

Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in…

Posted: February 13, 2025 at 2:44 am

Ad hoc announcement pursuant to Art. 53 LR

See the original post here:
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in...

Posted in Global News Feed | Comments Off on Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in…

Page 21234..1020..»